Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2/3 1

Status

Recruiting 2Not yet recruiting 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4Observational 1

Sponsor

Conditions

Myasthenia Gravis 5

Interventions

rozanolixizumab 5ravulizumab 5zilucoplan 4fludarabine 3Cyclophosphamide 3telitacicept 2inebilizumab 2talquetamab 1remibrutinib 1iptacopan 1efgartigimod alfa 1Therapeutics 1Prednisone 1Prednisolone 1Plasma Exchange 1Immunoglobulins, Intravenous 1HBM9161 1Cladribine 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Myasthenia Gravis × rozanolixizumab × 90 days × Clear all
NCT07246564 2026-05-22

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 4 Recruiting
40 enrolled

Myasthenia Gravis

NCT07570589 2026-05-11

REAL MG PRO

Centre Hospitalier Universitaire de Nice

Not yet recruiting
50 enrolled

Myasthenia Gravis

NCT06149559 2026-05-08

roMyG

UCB Pharma

Phase 2/3 Recruiting
12 enrolled

Myasthenia Gravis

NCT06540144 2026-05-08

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Enrolling by invitation
12 enrolled

Myasthenia Gravis

NCT07463521 2026-03-17

MyVision

UCB Pharma

Phase 3 Not yet recruiting
120 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡